QUOTE AND NEWS
Benzinga  May 21  Comment 
Analysts at Jefferies initiated coverage on shares of BioScrip (NASDAQ: BIOS) with a “buy” rating. The target price for BioScrip is set to $17. BioScrip's shares closed at $13.21 yesterday. Deutsche Bank initiated coverage on shares of...
StreetInsider.com  May 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/BioScrip%2C+Inc.+%28BIOS%29+Tops+Q1+EPS+by+2c/8319547.html for the full story.
Benzinga  Apr 24  Comment 
BioScrip (NASDAQ: BIOS) today announced the closing of the underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $12.00 per share, including 3,968,750 shares of common stock offered by certain selling...
StreetInsider.com  Apr 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioScrip+%28BIOS%29+Prices+12.5M+Common+Stock+Offering/8264754.html for the full story.
StreetInsider.com  Apr 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioScrip+%28BIOS%29+Plans+to+Refinance+Indebtedness+with+%24325M+Facility/8257340.html for the full story.
StreetInsider.com  Apr 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/BioScrip+%28BIOS%29+Announces+Common+Stock+Offering/8257216.html for the full story.
TechCrunch  Mar 19  Comment 
An iPhone app called Awesome Baby Names has a secret Game Boy Advance emulator built into it, as 9to5Mac has discovered. The emulator is easily unlocked via a simple sequence of taps (depicted below), but if you do want to unlock it you'd better...
StreetInsider.com  Mar 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/BioScrip+%28BIOS%29+Files+%24200M+Mixed+Shelf%3B+16M+Common+for+Holders/8193149.html for the full story.
Benzinga  Mar 12  Comment 
Turkcell Iletisim Hizmetleri AS (NYSE: TKC) shares moved up 3.16% to $16.63 at 10:39 am. The volume of Turkcell Iletisim Hizmetleri shares traded was 854% higher than normal. Turkcell's trailing-twelve-month ROE is 17.80%. Parametric Sound...
StreetInsider.com  Mar 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/BioScrip%2C+Inc.+%28BIOS%29+Tops+Q4+EPS+by+3c%3B+Guides+FY13+Revs+Above+Views/8174707.html for the full story.




RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS

BioScrip, Inc. (BIOS), based in Elmsford NY, is a specialty pharmacy services provider and pharmacy benefit manager. BioScrip was formed through the merger of MIM Corporation and Chronimed in March 2005. MIM originated from a company called Pro-Mark Holdings, which was a clinical management and consulting company that developed pharmacy networks and pharmacy benefit carve-out programs. In 1998, MIM acquired a traditional and specialty mail-service operation and officially became a full-service PBM and specialty company. Chronimed had been a pioneer in the specialty pharmacy industry and a leader in providing specialty pharmacy services for people with complex chronic health conditions. In 1996, Chronimed acquired StatScript Pharmacy, which was Chronimed Inc.'s wholly owned and operated retail chain. A key element of the company's growth strategy and a major consequence of the MIM-Chronimed deal was the increased exposure to higher-margin specialty pharmaceutical business.

Bioscrip operates two interrelated business segments, namely: Specialty Services, which is comprised of specialty pharmacy distribution and clinical management services and PBM Services, which is comprised of pharmacy benefit management and traditional mail services. The company's Specialty Services division distributes biotech and other high-cost injectable and infusible prescription medications, in addition to traditional tablets and capsules, and provides clinically focused case and therapy management programs to patients with chronic health conditions, genetic disorders, or have potentially life threatening or debilitating diseases. The division has two distinct distribution models. Firstly, a local or community based distribution model operating through community pharmacies, under which medication is dispensed to retail consumers at the point of sale or through home delivery. These patients typically have commercial prescription drug coverage or coverage through Medicare or Medicaid. And secondly, a national/regional specialty mail distribution model under which BIOS contracts with Plan Sponsors on an exclusive or preferred basis to dispense and ship injectable and infusible medications directly to a patient or to the patient s physician for administration. The company has 34 specialty pharmacies operating as full-service community retail pharmacies, carrying both traditional and specialty medications, under the "BioScrip" brand and located in major metropolitan areas across the United States. In addition, the company operates two infusion centers, one located in Burbank, California and the other in Livingston, New Jersey. PBM Services provide "plan sponsors" with a broad range of tailored cost-effective pharmacy benefit management services through the company's network of retail pharmacies and traditional mail service distribution facility. The company derives revenue through the sale of prescription drugs, and reimbursements for prescription drugs and services provided on behalf of third party payors, Medicare or Medicaid. On May 9, 2006, BIOS reported total revenues of $299.7M comprising of $203.6M Special Services (68% of total revenues) and $96.1M PBM Services (32% of total revenues).

On April 24, 2006, BIOS announced it had been selected by Centers for Medicare and Medicaid Services (CMS) as the national vendor for the initial phase of the new Competitive Acquisition Program (CAP) for certain Part B drugs and biologicals which will run for the period July 1, 2006 through December 31, 2006.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki